Your session is about to expire
← Back to Search
Pembrolizumab Post-IMRT for Thyroid Cancer
Study Summary
This trial will study the use of the drug pembrolizumab as an adjuvant (additional) treatment to radiation in patients with stage IVB cancer that has spread to the neck. The aim is to estimate how well the pembrolizumab works in prolonging the progression-free survival in these patients.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2024 Phase 2 trial • 57 Patients • NCT03004183Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I have not received a live vaccine in the last 30 days.My cancer is advanced but hasn’t spread to my neck.I am 18 or older with a diagnosis of anaplastic thyroid cancer.I am fully active or can carry out light work.I have an immune system disorder or have been on steroids or other immune-weakening drugs in the last week.I have had previous treatments targeting my immune system.My thyroid cancer has a specific mutation (BRAFV600E) and I can receive targeted therapy.I have finished radiation therapy, with or without chemotherapy.My organs are working well.You are pregnant, as shown by a recent urine test.I am not pregnant, not breastfeeding, and follow birth control guidelines.I am a male and agree to use contraception and not donate sperm.
- Group 1: Pembrolizumab
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Are new patients being accepted into this research study?
"The medical trial is still looking for patients, as of July 18th, 2022. This information can be found on clinicaltrials.gov, which also reports that the study was first posted on February 11th, 2020. They are recruiting for 35 participants from 1 location."
What other instances of research have there been with Pembrolizumab?
"Pembrolizumab is being trialed in 1000 different ongoing studies, with 122 of them in Phase 3. The majority of these trials are based in Houston, Texas; however, there are 36030 locations running Pembrolizumab clinical trials globally."
How many individuals are being monitored in this clinical research?
"That is accurate. The information available on clinicaltrials.gov reveals that this research is looking for volunteers at the moment. This study was first announced on February 11th, 2022 and has had one update since then on July 18th, 2022. So far, only 1 out of the 35 needed participants have been recruited."
Could you please provide more information on the risks of Pembrolizumab?
"Pembrolizumab falls into Phase 2 of clinical trials, meaning that while there is some data supporting its safety, there is currently no evidence to suggest that it is effective."
Share this study with friends
Copy Link
Messenger